A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT03897868

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03897868
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03897868. Randomized; double masking; primary purpose treatment. Start 2019-03-21 (actual); primary completion 2020-02-26 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
Acronym
HM_APOLLO
Condition
Hypertension
Intervention (Drug)
HCP1803
Intervention (Drug)
Amlodipine
Intervention (Drug)
Losartan
Intervention (Drug)
Placebo
Lead sponsor
Hanmi Pharmaceutical Company Limited (class: industry)

Record details

Record id
cardio:ct-nct03897868
Content hash
1436808dd24f7f10a2ad943f531d272211908bad99a0c4b2a11c9c73d97d67a1